Journal · Updated 2026-08-11
What Happens When You Stop a GLP-1: The Regain Data From SURMOUNT-4 and STEP-1, Read Straight
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
The short answer
These medications treat a chronic condition, and the withdrawal trials prove it. In SURMOUNT-4, everyone took tirzepatide for thirty-six weeks (losing about twenty-one percent on average), then half were switched to placebo: over the following year the placebo group regained roughly fourteen percent of body weight while the continuing group lost a further five-plus percent. In the STEP-1 extension, a year after stopping semaglutide participants had regained about two-thirds of what they'd lost, with cardiometabolic improvements reverting alongside. Regain isn't a willpower verdict — it's the biology the drug was suppressing resuming — and it reshapes the financial question from "what does a year cost" to "what does staying at goal cost," which is the honest frame for every price on this site.
What the trials actually did
SURMOUNT-4 (JAMA, 2023) is the clean experiment: a thirty-six-week open-label lead-in on tirzepatide for all participants, then randomization to continue or switch to placebo for fifty-two more weeks. Continuers kept losing — about five and a half percent more. Switchers regained about fourteen percent of body weight, giving back most though not all of the lead-in loss, with the gap between arms at week eighty-eight enormous. STEP-1's extension told the same story for semaglutide: one year after treatment ended, participants had regained roughly two-thirds of the seventeen-ish percent they'd lost, and blood pressure, lipids, and glycemic measures drifted back with the weight. Two readings matter. First, averages hide a spread — a minority maintain much better off-drug, especially with aggressive lifestyle structure — but the central tendency is regain, and planning around being the exception is a plan built on hope. Second, partial retention is real: neither trial's stop-arm returned fully to baseline within the year, so treatment wasn't erased, just substantially unwound.
Why regain happens
The drugs work by pharmacologically muting appetite signaling and slowing gastric emptying; stop the drug and that biology resumes at full volume — often louder, because weight loss itself triggers compensatory hunger-hormone shifts (ghrelin up, leptin down) and a lower resting energy expenditure that persist after the scale stops moving. The person who regains wasn't failing to try; they were re-entering a headwind the medication had been neutralizing. This is the same shape as hypertension returning when an antihypertensive stops, which is precisely the argument for thinking of GLP-1s as chronic therapy — and the argument insurers and patients keep colliding over, because chronic therapy at these prices is a different commitment than a "course."
What has evidence for stopping better
Honestly: less than the internet implies, but not nothing. Tapering rather than stopping cold is widely practiced and physiologically sensible, though trial evidence that it prevents regain is thin. Stepping down to a lower maintenance dose — the legitimate cousin of the microdosing pitch — keeps some pharmacology on board at lower cost and is a live research question rather than a proven strategy. Resistance training and high protein intake during and after treatment defend lean mass, which protects resting metabolism, the quiet variable in regain. Structured follow-up matters: the maintenance data across obesity medicine consistently favors people who keep measuring and keep an accountability structure after the drug stops. And re-starting is not failure — SURMOUNT-4's design is literally the evidence that resuming works. What doesn't have evidence: the idea that a few months of treatment "resets" anything permanently. The trials looked for that and found regain instead.
Pricing the real timeline
This is where regain science meets this site's actual beat. If maintenance is plausibly multi-year, the relevant numbers aren't first-year totals but sustainable annual run-rates: roughly twelve hundred to seventeen hundred dollars a year at the compounded floors, fifty-four hundred at brand Zepbound maintenance, three hundred at a twenty-five-dollar insured copay — and the delta between those compounds every year you stay at goal. It's also the strongest argument for keeping insurance pathways warm even while paying cash, for preferring programs with clean exits and re-entries (NexLife's come-back-anytime terms, LillyDirect's no-subscription structure) over prepaid lock-ins, and for treating any decision to stop as a clinical conversation with a taper plan and a re-start threshold — not a subscription cancellation. The drug companies, the trials, and your own biology are all telling you the same thing; the budget should hear it too.
Questions people ask
How much weight do people regain after stopping tirzepatide?
In SURMOUNT-4, participants switched to placebo after 36 weeks of tirzepatide regained about 14% of body weight over the following year, while those continuing lost a further ~5.5%. Regain was substantial but not complete — the stop group didn't return fully to baseline within the year. Averages hide a spread; the central tendency is regain.
Do you regain weight after stopping semaglutide?
On average, yes: in the STEP-1 extension, participants regained roughly two-thirds of their lost weight within a year of stopping, with blood pressure and metabolic improvements reverting alongside. A minority maintain better, particularly with strong lifestyle structure, but planning to be the exception is not a plan.
Why does weight come back after GLP-1s?
The medication suppresses appetite signaling and slows gastric emptying; stopping restores that biology — amplified by weight loss's own compensations (higher ghrelin, lower leptin, reduced resting energy expenditure). Regain is the treated condition resuming, the same way blood pressure returns when an antihypertensive stops, which is the case for viewing GLP-1s as chronic therapy.
Is there a way to stop a GLP-1 without regaining?
Nothing proven prevents it. Practices with rationale or partial evidence: tapering rather than stopping cold, stepping down to a lower maintenance dose, resistance training and protein to defend lean mass, and structured follow-up. Re-starting after regain works — the trials show it — so any stop should come with a clinical taper plan and a pre-agreed re-start threshold rather than a quiet cancellation.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.